Side-by-side comparison
NVS vs BSX — Side-by-side comparison
BSX screens cheaper on EV/FCF, BSX has the higher ROIC, BSX has grown revenue faster over five years, and BSX has the cleaner balance sheet by net debt / EBITDA.
NVS
Novartis AG
Price
$152.01
Market cap
$223.3B
Day %
N/A
BSX
Boston Scientific
Price
$57.78
Market cap
$154.2B
Day %
N/A
Peer Comparison
Target stock against 1 market-cap comparable peer.
Heat map: red worst to green best
NVS implied-growth snapshot
Simple static valuation context using owner earnings yield and realized growth.
EV/FCF
N/A
FCF yield
N/A
5Y rev CAGR
N/A
BSX implied-growth snapshot
Simple static valuation context using owner earnings yield and realized growth.
EV/FCF
41.6x
FCF yield
2.4%
5Y rev CAGR
15.2%
5Y indexed stock chart
Static Recharts view indexed to 100 from available annual per-share data.
Quality Scorecard
Build-time composite score for NVS.
Grade F
0
/ 100
Quality Radar0 – 20 per axis
Quality Scorecard
Build-time composite score for BSX.
Grade C
62
/ 100
Quality Radar0 – 20 per axis